
Kezar Board Rejects Unsolicited Concentra Proposal and Implements Short-Term Stockholder Rights Plan
Kezar Life Sciences Board Unanimously Rejects Concentra’s Acquisition Proposal and Implements Limited Duration Stockholder Rights Plan Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for immune-mediated diseases, announced today that its…